At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 target
Drug / intervention
sodium borocaptate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Postoperative Treatment of Glioblastoma With BNCT at the Petten Irradiation Facility
European Organisation for Research and Treatment of Cancer - EORTC·interventional·Posted Jan 27, 2003·Updated Jul 18, 2012
In Brief
A Phase 1 clinical trial evaluating sodium borocaptate and adjuvant therapy for Brain and Central Nervous System Tumors. Completed, enrolled 36 participants across 8 sites in 6 countries.
Detailed Summary
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of boron neutron capture therapy following surgery in treating patients with glioblastoma multiforme removed during surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain and Central Nervous System Tumors
CountriesAustria, Canada, France, Germany, Italy, Netherlands
Collaborators--
Timeline
Phase 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2002
First PostedJan 2003
Primary CompletionJul 2003
TodayJul 2026
First PostedJan 27, 2003
Enrollment StartJun 1, 2002
Primary CompletionJul 1, 2003
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 23.4 years ago
Interventions
sodium borocaptatedrug
adjuvant therapyprocedure